Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 406-260-5
CAS number: 58834-75-6
BTN; VPO CATALYST
Vanadyl pyrophosphate is used
in industrial applications as a catalyst, thus it is handled during
loading, unloading or maintenance of reactors.
Therefore, long-term dermal
and inhalative intakes are the possible exposure routes for worker,
while a contact for the general public can be excluded.
In addition to the assessment
of the long-term effects, a qualitative assessment according to
“Guidance on information requirements and chemical safety assessment,
Chapter R.8: Characterisation of dose [concentration]-response for human
health” (ECHA, May 2008) of
the local effects of vanadyl
pyrophosphate needs to be performed, since it was found to be irritating
to eyes as well as sensitising. Appropriate risk management measures
need to be identified.
The DNEL for oral and dermal
long-term exposure are derived from the no observed effect level
obtained in a 28-day oral repeated dose toxicity study performed
according to OECD guideline 407. Based on the observed mortality and
clinical findings, the NOAEL was found to be 200 mg/kg bw/d.
For calculation of the DNEL
for long-term inhalation systemic effects, route-to-route extrapolation
was performed in order to take into account differences between rat and
human exposure conditions. Therefore, the no observed effect level was
corrected by 1/0.38 and 6.7/10 regarding breathing volume and frequency.
Thus, the corrected starting point for workers was 176.3 mg/m3/d for
Subsequently other assessment
factors are listed, which have to be taken into account for the final
DNEL calculation: remaining interspecies-differences (2.5), intraspecies
differences (5), exposure duration (6). An additional assessment factor
(2) was used to consider the different absorption properties of the
respiratory tract and after oral intake.
The DNEL is calculated
according to the formula DNEL = (corrected starting point)/(overall AF).
Thus, the resulting DNEL for long-term inhalative systemic effects of
vanadyl pyrophosphate is 2.4 mg/m3for workers.
For the DNEL of systemic oral
effects a correction of the starting point is not required, since the
observed effect level was derived in a 28-day oral repeated dose
assessment factors are taken into account for the final DNEL
calculation: interspecies differences (4), remaining
interspecies-differences (2.5), intraspecies differences (5), exposure
As a consequence, the
resulting DNEL for long-term dermal systemic effects is 0.7 mg/kg bw/d
Vanadyl pyrophosphate is only used in industrial applications as a
catalyst, thus it is handled during loading, unloading or maintenance of
Due to the exclusively industrial use of vanadyl pyrophosphate, a
contact by the general public can be excluded. Therefore, DNELs for the
general population have not been derived.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again